Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy.
Psychiatry Investig. 2013 Jun;10(2):180-9. doi: 10.4306/pi.2013.10.2.180. Epub 2013 May 30.
Gene variants within the serotonin pathway have been associated with major depressive disorder (MDD) treatment outcomes, however a possible different modulation on pharmacological or psychological treatments has never been investigated.
One hundred sixty MDD patients were partially randomized to either inter-personal counseling (IPC) or antidepressants. The primary outcome was remission at week 8. Five serotonergic polymorphisms were investigated (COMT rs4680, HTR1A rs6295, HTR2A rs2224721, HTR2A rs7997012 and SLC6A4 rs421417).
IPC (n=43) and antidepressant (n=117) treated patients did not show any difference in remission rates at week 8 (corrected for baseline severity, age and center). None of the studied gene variants impacted on response and remission rates at week 8 neither in the IPC nor in the antidepressant group. An analysis of the whole sample showed a trend of association between rs7997012 AA genotype and a better treatment outcome.
Our study confirms that IPC is an effective psychological intervention comparable to antidepressants in mild-moderate MDD. Polymorphisms related to the serotonin system did not exert a major effect on clinical outcomes in none of the treatment groups.
血清素途径中的基因变异与重度抑郁症(MDD)的治疗结果有关,但从未研究过它们对药物或心理治疗可能产生的不同调节作用。
160 名 MDD 患者被部分随机分配至人际咨询(IPC)或抗抑郁药物治疗组。主要结局为第 8 周的缓解率。研究了 5 种血清素相关多态性(COMT rs4680、HTR1A rs6295、HTR2A rs2224721、HTR2A rs7997012 和 SLC6A4 rs421417)。
在第 8 周时,接受 IPC(n=43)和抗抑郁药物(n=117)治疗的患者在缓解率方面没有差异(校正基线严重程度、年龄和中心)。在 IPC 组和抗抑郁药物组中,研究的基因变异均未影响第 8 周时的反应和缓解率。对全样本的分析显示,rs7997012 AA 基因型与更好的治疗结果之间存在关联趋势。
我们的研究证实,IPC 是一种有效的心理干预措施,在轻度至中度 MDD 中与抗抑郁药物相当。在任何治疗组中,与血清素系统相关的多态性对临床结局都没有产生重大影响。